Zobrazeno 1 - 10
of 13
pro vyhledávání: '"David Hokey"'
Autor:
Dhanasekaran Sivakumaran, Gretta Blatner, Rasmus Bakken, David Hokey, Christian Ritz, Synne Jenum, Harleen M. S. Grewal
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Despite the widespread use of BCG, tuberculosis (TB) remains a global threat. Existing vaccine candidates in clinical trials are designed to replace or boost BCG which does not provide satisfying long-term protection. AERAS-402 is a replication-defic
Externí odkaz:
https://doaj.org/article/e3879b7a5ea64e3594a377e97420e50c
Autor:
Bernd Eisele, Martin Gengenbacher, Reginald Kidd, David McCown, Sheldon Morris, Steven Derrick, David Hokey, Dominick Laddy, Rosemary Chang, Megan Fitzpatrick, Leander Grode, Kamalakannan Velmurugan, Stefan H.E. Kaufmann, John Fulkerson, Michael J. Brennan
Publikováno v:
Vaccines, Vol 1, Iss 2, Pp 120-138 (2013)
The failure of current Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccines, given to neonates to protect against adult tuberculosis and the risk of using these live vaccines in HIV-infected infants, has emphasized the need for generating ne
Externí odkaz:
https://doaj.org/article/0faed53a9b714acc8f5dbb8a8015cef0
Autor:
Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, Michele Tameris, Soren T. Hoff, Zhongkai Shi, Dereck Tait, Ingrid Kromann, Morten Ruhwald, Kathryn Tucker Rutkowski, Barbara Shepherd, David Hokey, Ann M. Ginsberg, Willem A. Hanekom, Peter Andersen, Thomas J. Scriba, Mark Hatherill, Rachel Elizabeth Oelofse, Lynnett Stone, Anne Marie Swarts, Raida Onrust, Gail Jacobs, Lorraine Coetzee, Gloria Khomba, Bongani Diamond, Alessandro Companie, Ashley Veldsman, Humphrey Mulenga, Yolundi Cloete, Marcia Steyn, Hadn Africa, Lungisa Nkantsu, Erica Smit, Janelle Botes, Nicole Bilek, Simbarashe Mabwe
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 199:220-231
Global tuberculosis (TB) control requires effective vaccines in TB-endemic countries, where most adults are infected with Mycobacterium tuberculosis (M.tb).We sought to define optimal dose and schedule of H56:IC31, an experimental TB vaccine comprisi
Autor:
Rhea N. Coler, Tracey A. Day, Ruth Ellis, Franco M. Piazza, Anna Marie Beckmann, Julie Vergara, Tom Rolf, Lenette Lu, Galit Alter, David Hokey, Lakshmi Jayashankar, Robert Walker, Margaret Ann Snowden, Tom Evans, Ann Ginsberg, Steven G. Reed, The TBVPX-113 Study Team
Publikováno v:
npj Vaccines, Vol 3, Iss 1, Pp 1-9 (2018)
NPJ Vaccines
NPJ Vaccines
Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of improved TB vaccines that boost or replace BCG is a major global health goal. ID93 + GLA-SE is a fusion protein TB vaccine candidate combined with the Toll-like Rece
Autor:
Natalia Pendas Franco, Emiliano Calvo, Tamar Yablonski-Peretz, David Hokey, Victor Moreno, Peter Hellemans, Ravit Geva, Ruth Perets, Yue Guo, Qi Xia, Suzette Girgis, Nele Fourneau
Publikováno v:
Journal of Clinical Oncology. 37:2527-2527
2527 Background: JNJ-64457107 (JNJ-107) is an agonistic human monoclonal (IgG1) antibody targeting CD40, a novel target for anti-tumor immunotherapy with a central role in adaptive and innate immunity. Methods: JNJ-107 was administered intravenously
Autor:
David Hokey, Michele Tameris, Dawn Henson, Veerabadran Dheenadhayalan, Gretta Blatner, Bruce McClain, Robert Walker, Mark Hatherill, Videlis Nduba, Jahit Sacarlal, Glenda Gray, Jenny Hendriks, Maria Pau, Macaya Douoguih, Jerald Sadoff, Lewellys Barker
Publikováno v:
The Journal of Immunology. 194:73.4-73.4
Despite widespread use of BCG, tuberculosis (TB) remains a global threat, with 9 million new cases and 1.5 million deaths reported in 2013. Current vaccine candidates in clinical trials are designed to replace BCG or boost the variable efficacy obser
Publikováno v:
The Journal of Immunology. 194:207.2-207.2
One challenge to tuberculosis vaccine research is the lack of a correlate of immunity, which researchers are attempting to address through use of more high-throughput, high-data assays for assessing trial specimens. Multiparameter intracellular cytok
Autor:
Dawn Henson, Jaap van Dissel, Simone Joosten, Andrew Graves, Søren Hoff, Darius Soonawala, Corine Prines, Birgit Thierry-Carstensen, Lars Andreasen, Adriette de Visser, Else Agger, Tom Ottenhoff, Ingrid Kromann, Peter Andersen, David Hokey
Publikováno v:
The Journal of Immunology. 192:141.16-141.16
Approximately one third of the world’s population is infected with Mycobacterium tuberculosis. Developing novel vaccines to protect against pulmonary tuberculosis is a public health priority. In this study, a Hybrid 1 (H1) subunit vaccine containin
Autor:
David Hokey, Dawn O'Dee, Andrew Graves, Macaya Douoguih, Maria Pau, Isabella Versteege, Sharon Sheehan, Stephanie Harris, Bernard Landry, Jerald Sadoff, Helen McShane
Publikováno v:
The Journal of Immunology. 192:141.14-141.14
Developing an effective vaccine to prevent pulmonary tuberculosis represents a public health priority. AERAS-402 (adenovirus expressing a fusion of M.tuberculosis antigens 85A, 85B, and TB10.4) and MVA85A (Modified Vaccinia Anakara expressing Ag85A)
Autor:
David Hokey, Ramanan Pandian, Andrew Graves, Gavin Churchyard, Peggy Snowden, Macaya Douoguih, Bernard Landry
Publikováno v:
The Journal of Immunology. 190:179.6-179.6
One-third of the world's population is estimated to be infected with TB. The WHO no longer recommends that the currently available TB vaccine, BCG, be given to infants born to HIV+ mothers due to safety concerns. An improved vaccine that is effective